Attached files
file | filename |
---|---|
EX-99.2 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | pacb-20170426xex99_2.htm |
8-K - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | pacb-20170426x8k.htm |
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Condensed Consolidated Balance Sheets
(unaudited)
|
|||||
|
March 31, |
December 31, |
|||
(in thousands, except per share amounts) |
2017 |
2016 |
|||
Assets |
|||||
Current assets |
|||||
Cash and cash equivalents |
$ |
28,982 |
$ |
16,765 | |
Investments |
27,068 | 55,213 | |||
Accounts receivable |
10,441 | 11,421 | |||
Inventory |
15,348 | 15,634 | |||
Prepaid expenses and other current assets |
6,501 | 9,978 | |||
Total current assets |
88,340 | 109,011 | |||
Property and equipment, net |
42,449 | 14,560 | |||
Long-term restricted cash |
4,500 | 4,500 | |||
Other long-term assets |
219 | 9,813 | |||
Total assets |
$ |
135,508 |
$ |
137,884 | |
Liabilities and Stockholders’ Equity |
|||||
Current liabilities |
|||||
Accounts payable |
$ |
8,221 |
$ |
8,359 | |
Accrued expenses |
17,246 | 16,604 | |||
Deferred service revenue, current |
6,683 | 7,130 | |||
Other liabilities, current |
167 | 1,681 | |||
Notes payable, current |
3,123 |
— |
|||
Total current liabilities |
35,440 | 33,774 | |||
Deferred service revenue, non-current |
1,484 | 1,297 | |||
Deferred rent, non-current |
14,148 | 19 | |||
Other liabilities, non-current |
1,741 | 1,664 | |||
Notes payable, non-current |
13,302 | 16,106 | |||
Financing derivative |
208 | 356 | |||
Total liabilities |
66,323 | 53,216 | |||
|
|||||
Commitments and contingencies |
|||||
|
|||||
Stockholders’ equity |
|||||
Preferred Stock, $0.001 par value: |
|||||
Authorized 50,000 shares; No shares issued or outstanding |
— |
— |
|||
Common Stock, $0.001 par value: |
|||||
Authorized 1,000,000 shares; Issued and outstanding 93,540 and 92,677 shares at March 31, 2017 and December 31, 2016, respectively |
94 | 93 | |||
Additional paid-in-capital |
880,505 | 872,114 | |||
Accumulated other comprehensive income (loss) |
(3) | 5 | |||
Accumulated deficit |
(811,411) | (787,544) | |||
Total stockholders’ equity |
69,185 | 84,668 | |||
Total liabilities and stockholders’ equity |
$ |
135,508 |
$ |
137,884 |
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(unaudited)
|
||||||||||||
|
Three-Month Periods Ended March 31, |
|||||||||||
(in thousands, except per share amounts) |
2017 |
2016 |
||||||||||
Revenue: |
||||||||||||
Product revenue |
$ |
21,294 |
$ |
12,379 | ||||||||
Service and other revenue |
3,621 | 3,152 | ||||||||||
Contractual revenue |
— |
3,596 | ||||||||||
Total revenue |
24,915 | 19,127 | ||||||||||
Cost of revenue: |
||||||||||||
Cost of product revenue |
11,362 | 6,880 | ||||||||||
Cost of service and other revenue |
4,616 | 2,743 | ||||||||||
Total cost of revenue |
15,978 | 9,623 | ||||||||||
Gross profit |
8,937 | 9,504 | ||||||||||
Operating expense: |
||||||||||||
Research and development |
16,971 | 16,361 | ||||||||||
Sales, general and administrative |
15,265 | 11,708 | ||||||||||
Total operating expense |
32,236 | 28,069 | ||||||||||
Operating loss |
(23,299) | (18,565) | ||||||||||
Interest expense |
(838) | (779) | ||||||||||
Other income (expense), net |
270 | (8) | ||||||||||
Net loss |
(23,867) | (19,352) | ||||||||||
Other comprehensive loss: |
||||||||||||
Unrealized gain on investments |
(8) | 48 | ||||||||||
Comprehensive loss |
$ |
(23,875) |
$ |
(19,304) | ||||||||
|
||||||||||||
Net loss per share: |
||||||||||||
Basic and diluted net loss per share |
$ |
(0.26) |
$ |
(0.23) | ||||||||
Shares used in computing basic and diluted net loss per share |
92,970 | 83,604 | ||||||||||
|
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Condensed Consolidated Statements of Cash Flows
(unaudited)
|
|||||
|
Three-Month Periods Ended March 31, |
||||
(in thousands) |
2017 |
2016 |
|||
Cash flows from operating activities |
|||||
Net loss |
$ |
(23,867) |
$ |
(19,352) | |
Adjustments to reconcile net loss to net cash used in operating activities |
|||||
Depreciation |
2,850 | 848 | |||
Amortization of debt discount and financing costs |
319 | 268 | |||
Stock-based compensation |
4,985 | 4,581 | |||
Other items |
(145) | 74 | |||
Changes in assets and liabilities |
|||||
Accounts receivable |
980 | (2,865) | |||
Inventory |
366 | (2,119) | |||
Prepaid expenses and other assets |
3,377 | 4,709 | |||
Accounts payable |
(5,929) | (39) | |||
Accrued expenses |
562 | (3,350) | |||
Deferred service revenue |
(260) | (705) | |||
Deferred contractual revenue |
— |
(3,596) | |||
Other liabilities |
92 | 1,279 | |||
Net cash used in operating activities |
(16,670) | (20,267) | |||
Cash flows from investing activities |
|||||
Purchase of property and equipment |
(2,668) | (457) | |||
Disposal of property and equipment |
— |
111 | |||
Purchase of investments |
(10,419) | (43,383) | |||
Sales of investments |
3,662 | 4,949 | |||
Maturities of investments |
34,905 | 15,539 | |||
Net cash provided by (used in) investing activities |
25,480 | (23,241) | |||
Cash flows from financing activities |
|||||
Proceeds from issuance of common stock from equity plans |
3,407 | 3,423 | |||
Proceeds from issuance of common stock from at-the-market equity offering, net of issuance costs |
— |
26,536 | |||
Net cash provided by financing activities |
3,407 | 29,959 | |||
Net decrease in cash and cash equivalents |
12,217 | (13,549) | |||
Cash and cash equivalents at beginning of period |
16,765 | 33,629 | |||
Cash and cash equivalents at end of period |
$ |
28,982 |
$ |
20,080 | |
|
|||||
Supplemental disclosure of non-cash investing and financing activities |
|||||
Changes in unpaid property and equipment |
$ |
5,791 |
$ |
24 | |
Changes in deposits for property and equipment paid in prior period |
$ |
9,694 |
$ |
— |
|
Property and equipment paid by landlord |
$ |
12,600 |
— |